Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of MIL62 plus lenalidomide in CD20 antibody-refractory follicular lymphoma
CTR20210442Phase 3Active
- Sponsor
- Mabworks Biotech
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Bejescin in follicular lymphoma (FL), sponsored by Mabworks Biotech. Started Jun 2021; status: active.
02
Drugs
Bejescin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20210442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210442.